19:38 , Apr 27, 2018 |  BC Week In Review  |  Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will...
23:10 , Aug 1, 2017 |  BC Extra  |  Company News

Management tracks: Bicycle, ReNetX, ALK-Abello

Peptide company Bicycle Therapeutics Ltd. (Cambridge, U.K.) named Lee Kalowski CFO. He was CFO of Tokai Pharmaceuticals Inc. , which merged with Otic Pharma Ltd. to form Novus Therapeutics Inc. (NASDAQ:NVUS). Neurology play ReNetX Bio...
06:12 , Jul 28, 2017 |  BC Week In Review  |  Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp ( faster-acting insulin aspart , NN1218) or 0.15...
19:53 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Adocia starts Phase I trial of BioChaperone glucagon to treat Type I diabetes

Adocia S.A. (Euronext:ADOC) began a Phase I trial to compare 2 formulations of subcutaneous BioChaperone glucagon to GlucaGen HypoKit from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) in about 27 patients with Type I diabetes. Patients will...
00:41 , Feb 3, 2017 |  BC Week In Review  |  Company News

Adocia, Lilly deal

Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million up front for exclusive, worldwide rights to the ultra-fast-acting...
23:13 , Jan 27, 2017 |  BC Extra  |  Company News

Lilly returns diabetes candidate to Adocia

Adocia S.A. (Euronext:ADOC) sank EUR 12.67 (31%) to EUR 27.60 after it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

BioChaperone insulin combo: Phase Ib started

Adocia began a double-blind, double-dummy, 3-way crossover, German Phase Ib trial of subcutaneous BioChaperone Combo given before a meal on 3 consecutive days in 36 patients. The trial will compare BioChaperone Combo vs. subcutaneous Humalog...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BioChaperone PDGF-BB: Development halted

Adocia said it will halt development of BioChaperone PDGF-BB to treat diabetic foot ulcers after top-line data from a double-blind, Indian Phase III trial in 252 patients showed that 4 ug/cm 2 BioChaperone PDGF-BB spray...
07:00 , Aug 26, 2016 |  BC Extra  |  Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...